Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 20, 2025 08:30 ET | Source: Stemline Therapeutics, Inc.

Menarini Group Announces Collaboration with VisualDx to Aid in Identifying People Who May Have Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

BPDCN is an aggressive hematologic malignancy with a historically poor prognosisVisualDx is a clinical decision support system used by more than 2,300 hospitals, clinics, and medical schools around...
February 21, 2025 08:30 ET | Source: Stemline Therapeutics, Inc.

Tempus and Stemline Therapeutics, Inc., A Subsidiary of the Menarini Group, Announce Collaboration to Implement Tempus Next, an AI-Enabled Care Pathway Intelligence Platform to Support Patients with Metastatic Breast Cancer

Up to 50% of patients with ER+/HER2- mBC could develop ESR1 mutations as a result of prior exposure to endocrine therapy in the metastatic setting. Testing to identify these mutations can help...
January 10, 2025 09:00 ET | Source: Stemline Therapeutics, Inc.

Menarini Group and Insilico Medicine Enter a Second Exclusive Global License Agreement for an AI Discovered Preclinical Asset Targeting High Unmet Needs in Oncology

This is the second asset Menarini Group has inlicensed from Insilico Medicine which was discovered through their generative AI platform, similar to the preclinical stage KAT6 inhibitor (MEN2312)...
May 04, 2020 07:00 ET | Source: Stemline Therapeutics, Inc.

Menarini Group to Acquire Stemline Therapeutics in Transaction Valued at Up to $677 Million

Acquisition of Stemline establishes Menarini’s presence in the U.S. biopharmaceutical oncology market Menarini will support further development of Stemline’s ELZONRIS® and enable global expansion by...
March 13, 2020 16:45 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Reports Fourth Quarter 2019 Financial Results

Net revenue for ELZONRIS® was $11.8 million for the fourth quarterConference call and live webcast scheduled for Monday, March 16th, at 8:00 AM ET NEW YORK, March 13, 2020 (GLOBE NEWSWIRE) --...
March 11, 2020 16:05 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics to Host Conference Call on Fourth Quarter 2019 Financial Results on March 16, 2020

NEW YORK, March 11, 2020 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
February 26, 2020 07:30 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics to Present at the Cowen 40th Annual Health Care Conference

NEW YORK, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
January 13, 2020 16:15 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Announces Preliminary 2019 Net Revenues for ELZONRIS® (tagraxofusp) and Highlights Commercial and Clinical Growth Drivers

NEW YORK, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
January 08, 2020 16:15 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference

NEW YORK, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
December 10, 2019 08:00 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Recaps ELZONRIS Clinical Data Presentations in Patients with Myelofibrosis (oral presentation) and Multiple Myeloma at the 61st American Society of Hematology (ASH) Annual Meeting

NEW YORK, Dec. 10, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...

Next Page keyboard_arrow_right